Browse result page of CancerPDF Database
Please click on CancerPDF_ID for detailed information about peptide.
| CancerPDF_ID | Peptide seq | Protein Name | Fluid | Mass/Z | Profiling Technique | Cancer Type | Expression Regulation | PUBMED ID |
|---|---|---|---|---|---|---|---|---|
| CancerPDF_ID34 | NGFKSHALQLN | Complement C4 precursor | Serum | 1228.65 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID35 | NGFKSHALQLNNR | Complement C4 precursor | Serum | 1498.91 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID36 | NGFKSHALQLNNRQ | Complement C4 precursor | Serum | 1626.85 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID37 | NGFKSHALQLNNRQI | Complement C4 precursor | Serum | 1739.93 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID38 | NGFKSHALQLNNRQIR | Complement C4 precursor | Serum | 1895.99 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID39 | GLEEELQFSLGSKINV | Complement C4 precursor | Serum | 1762.87 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID40 | GLEEELQFSLGSKINVKVGGNS | Complement C4 precursor | Serum | 2305.2 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID41 | GLEEELQFSLGSKINVKVGGNSKGTL | Complement C4 precursor | Serum | 2704.13 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID42 | GLEEELQFSLGSKINVKVGGNSKGTLKVLR | Complement C4 precursor | Serum | 3200.52 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID43 | TLEIPGNSDPNMIPDGDFNSYVR | Complement C4 precursor | Serum | 2551.06 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID44 | TLEIPGNSDPNFIPDGDFNSYVR | Complement C4 precursor | Serum | 856.33 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID45 | PDGDFNSYVR | Complement C4 precursor | Serum | 585.23 | MALDI-TOF | Metastatic thyroid carcinomas | NA | 16896061 |
| CancerPDF_ID873 | TLEIPGNSDPNMIPDGDFNSYVR | Complement C4-A | Plasma | "1276.08, 851.05" | LC-MS | Ductal adenocarcinoma of the pancreas (DAP) | NA | 19795908 |
| CancerPDF_ID1050 | NGFKSHALQLNNR | Complement C4 precursor | Serum | 1498.91 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1, 809 and 1 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1051 | NGFKSHALQLNNRQ | Complement C4 precursor | Serum | 1626.85 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.09, 0.88 and 2.78 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1052 | NGFKSHALQLNNRQI | Complement C4 precursor | Serum | 1739.93 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =0.75, 0.66 and 2.75 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1053 | NGFKSHALQLNNRQIR | Complement C4 precursor | Serum | 1895.99 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =1.27, 3.33 and 2.95 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1054 | GLEEELQFSLGSKINV | Complement C4 precursor | Serum | 1762.87 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "For bladder (Lower) and for breast (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =1.62, 0.01 and 3.16 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1055 | GLEEELQFSLGSKINVKVGGNS | Complement C4 precursor | Serum | 2305.2 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =3.75, 2.56 and 3.49 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1056 | GLEEELQFSLGSKINVKVGGNSKGTL | Complement C4 precursor | Serum | 2704.13 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | "Upregulated in cancer vs normal with Ratio of median intensity (patients/Controls) =61, 49 and 133 in prostate, bladder and breast cancer respectively" | 16395409 |
| CancerPDF_ID1057 | GLEEELQFSLGSKINVKVGGNSKGTLKVLR | Complement C4 precursor | Serum | 3200.52 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | NA | 16395409 |
| CancerPDF_ID1058 | TLEIPGNSDPNMIPDGDFNSYVR | Complement C4 precursor | Serum | 2551.06 | MALDI-TOF | "Advanced Prostate, Breast and Bladder cancer" | NA | 16395409 |
| CancerPDF_ID1923 | QGSFQGGFR | Complement C4-A | Serum | 982.46208 | LC-MS | Colorectal cancer | NA | 21136997 |
| CancerPDF_ID3157 | SHALQLNN | Complement C4-A | Plasma | 895.4512 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3158 | SHALQLNNR | Complement C4-A | Plasma | 1051.5523 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3159 | VGGNSKGTLKVL | Complement C4-A | Plasma | 1171.6925 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3160 | VGGNSKGTLKVLR | Complement C4-A | Plasma | 1327.7936 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3161 | SHALQLNNRQIR | Complement C4-A | Plasma | 1448.796 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3162 | NGFKSHALQLNNR | Complement C4-A | Plasma | 1497.7801 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3163 | YALLHLLLHEGKAEM | Complement C4-A | Plasma | 1736.9284 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3164 | QIRGLEEELQFSLGSK | Complement C4-A | Plasma | 1832.9632 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3165 | QIRGLEEELQFSLGSKINV | Complement C4-A | Plasma | 2159.1586 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3166 | ALEILQEEDLIDEDDIPVR | Complement C4-A | Plasma | 2224.1111 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3167 | LDHRGRTLEIPGNSDPNMIPDG | Complement C4-A | Plasma | 2403.1601 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3168 | TLEIPGNSDPNMIPDGDFNSYVR | Complement C4-A | Plasma | 2550.1697 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3169 | GRTLEIPGNSDPNMIPDGDFNSYV | Complement C4-A | Plasma | 2607.1911 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3170 | GRTLEIPGNSDPNMIPDGDFNSYVR | Complement C4-A | Plasma | 2763.2922 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3171 | VLQIEKEGAIHREELVYELNPLDHR | Complement C4-A | Plasma | 2999.5829 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID3172 | VLQIEKEGAIHREELVYELNPLDHRG | Complement C4-A | Plasma | 3056.6043 | LC-MS | Normal | NA | 21136997 |
| CancerPDF_ID8672 | AACAQLNDFLQEYGTQGCQV | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8715 | AQLNDFLQEYGTQGCQV | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8717 | ARVQQPDCREPFLSCCQFAES | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8731 | CCQDGVTRLPM | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8737 | DCREPFLSC | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8738 | DCREPFLSCC | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8739 | DCREPFLSCCQ | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8743 | DDPDAPLQPVTPLQLFEG | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8746 | DFNSYVRV | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID8749 | DGDFNSYVRV | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9220 | SDPNMIPDGDF | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9305 | TLEIPGNSDPNMIPDGDF | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9306 | TLEIPGNSDPNMIPDGDFNS | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9405 | VQQPDCREPFLSCCQFAES | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9447 | YVRVTASDPLD | Complement C4-A | Ascites fluid | NA | LTQ-Orbitrap XL | Ovarian cancer | Uniquely expressed in ovarian cancer patient | 24694173 |
| CancerPDF_ID9453 | SHALQLNNR | Complement C4-A/Complement C4-B | Plasma | 1052.56 | MALDI-TOF | Colorectal cancer | "Intensity was similar to controls, controversially, in adenoma and CRC groups was highest. " | 26379225 |
| CancerPDF_ID9458 | LQLNNRQIR | Complement C4-A/Complement C4-B | Plasma | 1154.68 | MALDI-TOF | Colorectal cancer | "Intensity was similar to controls, controversially, in adenoma and CRC groups was highest. " | 26379225 |
| CancerPDF_ID9460 | ALQLNNRQIR | Complement C4-A/Complement C4-B | Plasma | 1225.72 | MALDI-TOF | Colorectal cancer | "Intensity was similar to controls, controversially, in adenoma and CRC groups was highest. " | 26379225 |
| CancerPDF_ID9466 | GLEEELQFSLGSK | Complement C4-A/Complement C4-B | Plasma | 1436.72 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis than control groups and an opposite trend in adenoma and CRC group. | 26379225 |
| CancerPDF_ID9467 | SHALQLNNRQIR | Complement C4-A/Complement C4-B | Plasma | 1449.77 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis group than adenoma and CRC groups | 26379225 |
| CancerPDF_ID9469 | NGFKSHALQLNNR | Complement C4-A/Complement C4-B | Plasma | 1499.79 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis group than adenoma and CRC groups | 26379225 |
| CancerPDF_ID9476 | GFKSHALQLNNRQIR | Complement C4-A/Complement C4-B | Plasma | 1782 | MALDI-TOF | Colorectal cancer | Higher intensity in liver metastasis than adenoma and CRC groups. | 26379225 |
| CancerPDF_ID9479 | GLEEELQFSLGSKINVK | Complement C4-A/Complement C4-B | Plasma | 1891.02 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
| CancerPDF_ID9480 | NGFKSHALQLNNRQIR | Complement C4-A/Complement C4-B | Plasma | 1896.03 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
| CancerPDF_ID9481 | NGFKSHALQLNNRQIR(NH4) | Complement C4-A/Complement C4-B | Plasma | 1913.01 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
| CancerPDF_ID9492 | GLEEELQFSLGSKINVKVGGNSK | Complement C4-A/Complement C4-B | Plasma | 2433.3 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
| CancerPDF_ID9610 | GFKSHALQLNNRQ | Complement C4-A | Serum | 504.93 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9611 | GFKSHALQLNNRQI | Complement C4-A | Serum | 542.63 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9612 | NGFKSHALQLNNRQ | Complement C4-A | Serum | 542.95 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9613 | HALQLNN | Complement C4-A | Serum | 405.2 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9614 | SHALQLNN | Complement C4-A | Serum | 448.72 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9615 | EEELQFSLGS | Complement C4-A | Serum | 569.76 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9616 | NGFKSHALQLNNR | Complement C4-A | Serum | 500.27 | LC-MS | Lung adenocarcinoma | "Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" | 21533267 |
| CancerPDF_ID9934 | NGFKSHALQLNNRQ | Complement C4-A | Serum | NA | LC-MS | Breast cancer | Differentially expressed between cancer vs control | 21124649 |
| CancerPDF_ID10354 | VQLQDVPRGQVVKGSVF | Complement C4-A | Urine | 1856.0386 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10509 | KPRLLLFSPSVVHLGVPLSVG | Complement C4-A | Urine | 2215.3122 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10578 | NGFKSHALQLNNRQIRGLEEE | Complement C4-A | Urine | 2453.2529 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID10581 | VRVTASDPLDTLGSEGALSPGGVASL | Complement C4-A | Urine | 2469.2767 | MALDI-TOF | Muscle-invasive bladder cancer | Differentially expressed between cancer vs normal samples | 21805675 |
| CancerPDF_ID12677 | DDPDAPLQPVTPLQLFEGRRN | Complement C4 | Serum | NA | LC-MS | Renal cell carcinaoma | Upregulated in cancer v/s Normal | 25168216 |
| CancerPDF_ID12710 | GFKSHALQLNNRQI | Complement C4 | Serum | 1625.946 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.68 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.78, Upregulated in BC vs healthy with 0.763 fold change" | 27058005 |
| CancerPDF_ID12711 | NGFKSHALQLNNRQ | Complement C4 | Serum | 1626.912 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.56 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.80, Upregulated in BC vs healthy with 0.754 fold change" | 27058005 |
| CancerPDF_ID12712 | NGFKSHALQLNNRQI | Complement C4 | Serum | 1739.971 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.76 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 0.83, Upregulated in BC vs healthy with 0.796 fold change" | 27058005 |
| CancerPDF_ID12713 | GFKSHALQLNNRQIR | Complement C4 | Serum | 1782.012 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 1.73 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.16, Upregulated in BC vs healthy with 1.092 fold change" | 27058005 |
| CancerPDF_ID12714 | NGFKSHALQLNNRQIR | Complement C4 | Serum | 1896.068 | MALDI-TOF | Breast cancer | "Upregulated with the fold change of 0.45 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.00, Upregulated in BC vs healthy with 0.968 fold change" | 27058005 |
| CancerPDF_ID12757 | NGFKSHALQLNNRQIR | Complement C4eB-like Isoform 1 | Serum | 1898.9 | MALDI-TOF | Cervical cancer | Upregulated in Cervical squamous cell carcinoma vs healthy | 26282206 |